The gut mycobiome: The overlooked constituent of clinical outcomes and treatment complications in patients with cancer and other immunosuppressive conditions.
Guardado en:
Autores principales: | Jessica R Galloway-Peña, Dimitrios P Kontoyiannis |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5a9d0152c66143dcad17e6d494a71a7e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Low-volume toolbox for the discovery of immunosuppressive fungal secondary metabolites.
por: Erwin Berthier, et al.
Publicado: (2013) -
Characterization of the oral fungal microbiome (mycobiome) in healthy individuals.
por: Mahmoud A Ghannoum, et al.
Publicado: (2010) -
Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia
por: Sarah Robinson, et al.
Publicado: (2020) -
TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
por: V. A. Kozlov, et al.
Publicado: (2017) -
Poor immunological recovery among severely immunosuppressed antiretroviral therapy-naïve Ugandans
por: Nanzigu S, et al.
Publicado: (2013)